Buradasınız

Anasayfa » Content

Konvansiyonel veya İntensif İnsülin Tedavisi Gören Diyabetli Hemodiyaliz Hastalarında Biyokimyasal Parametreler

Analysis of Biochemical Markers in Diabetic Hemodialysis Patients on Conventional or Intensive Insulin Therapy

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
OBJECTIVE: The objective of this study was to compare intensive and conventional insulin therapies with regards to HbA1c, serum lipids, and other biochemical markers. METHODS: This was a retrospective study investigating data from 44 insulin-dependent diabetic hemodialysis patients followed in our hemodialysis unit. Fifteen of the patients were on conventional therapy and 29 were on intensive therapy. RESULTS: Of the patients 34% were women, the mean age was 60±10 years, duration of diabetes 18±8 years and dialysis duration 3±2 years. Weight gain between dialysis sessions was 2570±768 g and dry weight was 64.6±1.3 kg. There was no significant difference between the two treatments in terms of HbA1c, CRP, hemoglobin, urea, creatinine, uric acid, albumin and electrolytes (p>0.05). Although total cholesterol and triglyceride levels were lower in the intensive treatment group than that conventional treatment grap the difference was not statistically significant (p>0.05). LDL and HDL levels were not statistically different between the study groups (p>0.05). CONCLUSIONS: There was no statistically significant difference between conventional and intensive insulin treatments in terms of HbA1c or other biochemical markers.
Bookmark/Search this post with
Abstract (Original Language): 
AMAÇ: Bu çalışmanın amacı, intensif ve konvansiyonel insülin tedavi yöntemlerinin, HbA1c düzeyi, serum lipidleri ve diğer biyokimyasal parametreler yönünden karşılaştırılmasıdır. YÖNTEM: Çalışma, hemodiyaliz ünitemizde takip edilmekte olan 44 insülin bağımlı diyabetik hemodiyaliz hastasının verileri retrospektif incelenerek gerçekleştirildi. Hastaların 15’i konvansiyonel, 29’u intensif tedavi görüyordu. BULGULAR: Hastaların %34’ü kadın, ortalama yaş 60±10 yıl, ortalama diyabet süresi 18±8 yıl, ortalama diyaliz süresi 3±2 yıldı. Diyaliz arası kilo alım ortalamaları 2570±768 g, kuru ağırlıkları 64.6±1.3 kg bulundu. İnsülin kullanım şekline göre HbA1c, CRP, hemoglobin, üre, kreatinin, ürik asit, albumin ve elektrolitler arasında istatistiksel olarak anlamlı bir farklılık bulunmadı (p>0.05). İntensif insülin kullanan olguların total kolesterol ve trigliserid düzeyleri, konvansiyonel insülin kullanan olgulardan daha düşük olmakla birlikte fark istatistiksel olarak anlamlı değildi (p>0.05). LDL ve HDL düzeyleri arasında istatistiksel olarak anlamlı bir farklılık bulunmadı (p>0.05). SONUÇ: Konvansiyonel ve intensif insülin tedavileri arasında HbA1c de dahil olmak üzere biyokimyasal değerler yönünden anlamlı farklılık bulunmadı.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_18_pp_15-19.pdf
  • 1
15-19
  • Turkish

REFERENCES

References: 

1. United States Renal Data System, USRDS 2001 Annual Data
Report. 2001. The National Institutes of Health, National Institute
of Diabetes and Digestive and Kidney Diseases
2. The effect of intensive treatment of diabetes on the development
and progression of long-term complications in insulin-dependent
diabetes mellitus. The Diabetes Control and Complications Trial
Research Group. N Engl J Med 1993; 329(14):977-986
3. Intensive blood-glucose control with sulphonylureas or insulin
compared with conventional treatment and risk of complications
in patients with type 2 diabetes (UKPDS 33). UK Prospective
Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837-
853
4. Iglesias P, Diez JJ: Insulin therapy in renal disease. Diabetes Obes
Metab 2008
5. Graham I, Atar D, Borch-Johnsen K, et al: European guidelines
on cardiovascular disease prevention in clinical practice: executive
summary. Fourth Joint Task Force of the European Society of
Cardiology and other societies on cardiovascular disease prevention
in clinical practice (constituted by representatives of nine societies
and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14
Suppl 2:E1-40
6. Nathan DM, Cleary PA, Backlund JY, et al: Intensive diabetes
treatment and cardiovascular disease in patients with type 1
diabetes. N Engl J Med 2005; 353(25):2643-2653
7. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy
and carotid intima-media thickness in type 1 diabetes mellitus. N
Engl J Med 2003; 348(23):2294-2303
8. Cleary PA, Orchard TJ, Genuth S, et al: The effect of intensive
glycemic treatment on coronary artery calcification in type 1
diabetic participants of the Diabetes Control and Complications
Trial / Epidemiology of Diabetes Interventions and Complications
(DCCT/EDIC) Study. Diabetes 2006; 55(12):3556-3565
ÖĞÜTMEN: Diyabetli Hemodiyaliz Hastalarında
Konvansiyonel veya İntensif İnsülin Tedavisi
Cilt/Vol. 18, No, 1, 2009 Sayfa/Page 15-19
18
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
19
9. Tuomilehto J, Borch-Johnsen K, Molarius A, et al: Incidence of
cardiovascular disease in Type 1 (insulin-dependent) diabetic
subjects with and without diabetic nephropathy in Finland.
Diabetologia 1998; 41(7):784-790
10. Morioka T, Emoto M, Tabata T, et al: Glycemic control is a predictor
of survival for diabetic patients on hemodialysis. Diabetes Care
2001; 24(5):909-913
11. Oomichi T, Emoto M, Tabata T, et al: Impact of glycemic control
on survival of diabetic patients on chronic regular hemodialysis: a
7-year observational study. Diabetes Care 2006; 29(7):1496-1500.
12. Suzuki Y, Arakawa M: The treatment of the uraemic diabetic.
Are we doing enough? A view from Japan. Fumitake Gejyo and
Collaborate Study Group. Nephrol Dial Transplant 1995; 10 Suppl
7:47-55
ÖĞÜTMEN: Diyabetli Hemodiyaliz Hastalarında
Konvansiyonel veya İntensif İnsülin Tedavisi
13. Tzamaloukas AH, Murata GH, Zager PG, et al: The relationship
between glycemic control and morbidity and mortality for diabetics
on dialysis. ASAIO J 1993; 39(4):880-885
14. Wu MS, Yu CC, Yang CW, et al: Poor pre-dialysis glycaemic
control is a predictor of mortality in type II diabetic patients on
maintenance haemodialysis. Nephrol Dial Transplant 1997;
12(10):2105-2110
15. Loipl J, Schmekal B, Biesenbach G: Long-term impact of chronic
hemodialysis on glycemic control and serum lipids in insulintreated
type 2-diabetic patients. Ren Fail 2005; 27(3):305-308

Thank you for copying data from http://www.arastirmax.com